Dysport, Nuceiva (botulinum toxin type a) is an unknown pharmaceutical. Botulinum toxin type a was first approved as Dysport on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
|Common Name||Botulinum toxin type a|
|Indication||blepharospasm, dystonia, fissure in ano, genetic skin diseases, muscle rigidity, skin aging, strabismus|
|Drug Class||Fluoroquinolone derivatives, nonantibacterial indications (e.g., antineoplastic antibiotics)|